Fig. 6

Assessment of immune infiltration, sensitivity of ICIs and target therapy. A Abundance of 22 different immune cells inferred by CIBERSORT for different risk groups. B Different expression of immune checkpoints (PD-L1 and CTLA-4) for different risk groups. C, D Different expression of VEGFA, VEGFB, PlGF, VEGFR1, VEGFR2, and NRP1 within low and high-risk groups. *p < 0.05; **p < 0.01; ***p < 0.001; ns: no significant